Abbott Reports Solid Q4 Results On Growth Across Divisions

The company's operational sales from continuing operations increased 10.2% over the prior year quarter to $5.4 billion. Abbott's branded generic drug business in developed markets is in the process of being acquired by Mylan and therefore has been reported as discontinued operations in the financial report. Discontinued operations registered $522 million of sales in the quarter. Net earnings, including discontinued operations, increased by 18.6% to about $1.1 billion or $0.71 per share, which wa...